GHRS GH Research PLC
Price Chart
Executive Summary
GH Research PLC announced the publication of Phase 2b trial results for its lead candidate GH001 in treatment-resistant depression (TRD) in JAMA Psychiatry, along with a secondary analysis showing efficacy independent of prior antidepressant treatment failures. These peer-reviewed findings support the drug's potential as a practice-changing therapy and de-risk the upcoming Phase 3 program.
Actionable Insight
The JAMA Psychiatry publication adds strong external validation to GH001's efficacy, increasing confidence in the upcoming Phase 3 program. Traders should monitor for Phase 3 trial initiation, regulatory feedback, and potential partnership announcements, which could act as near-term catalysts.
Key Facts
- Phase 2b results for GH001 in TRD published in JAMA Psychiatry, a top-tier peer-reviewed journal.
- GH001 achieved a statistically significant MADRS reduction of −15.5 points vs placebo by Day 8 (P<0.0001).
- New analysis shows remission rates remained high (53.9%–63.6% on Day 8, 61.5%–85.7% at Month 6) regardless of prior antidepressant failures, breaking the STAR*D trend.
- No correlation between prior treatment failures and MADRS improvement (r=−0.13; P=0.44 at Day 8).
- Data supports advancement into global pivotal Phase 3 trials.
Financial Impact
Significant de-risking of clinical pipeline; increases probability of regulatory success and partnership potential. Market cap currently $831M reflects early-stage valuation with substantial upside if Phase 3 succeeds.
Risk Factors
- Phase 2b results may not replicate in larger Phase 3 trials.
- Regulatory pathways for TRD treatments remain complex and uncertain.
- Competition from other rapid-acting antidepressants (e.g., esketamine, psychedelics in development).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262385 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
26d ago
|
424B5
| $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $20.12 (+9.41%) |
|
May 14, 2026
26d ago
|
6-K
| $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $20.12 (−9.41%) |
|
May 14, 2026
26d ago
|
Press Release
| $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $20.12 (−9.41%) |
|
May 13, 2026
27d ago
|
6-K
| $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $20.12 (+9.41%) |
|
Apr 29, 2026
5w ago
|
424B5
| $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $20.12 (−5.01%) |
|
Apr 1, 2026
9w ago
|
3
| $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $20.12 (+38.09%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $20.12 (+47.40%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $15.17 $15.52 | ▲ +2.31% | ▲ +4.54% | $20.12 (+32.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access